<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554330</url>
  </required_header>
  <id_info>
    <org_study_id>2017-GZ15</org_study_id>
    <nct_id>NCT03554330</nct_id>
  </id_info>
  <brief_title>Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Communication</brief_title>
  <acronym>CURB</acronym>
  <official_title>The Combined Use of Radiofrequency-catheter-ablation and Balloon-atrial-septostomy (CURB) in the Creation of a Stable Inter-atrial Communication:a Preliminary Study in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Though graded balloon-atrial-septostomy (BAS) has been accepted as an effective palliative
      therapy for severe pulmonary arterial hypertension, spontaneous closure of septostomy is not
      uncommon. Radiofrequency-catheter-ablation (RFA), which has the potential to cause
      irreversible damage around the rim of created inter-atrial communication, might contribute to
      prevent the spontaneous closure. In patients with severe pulmonary arterial hypertension, the
      combined use of RFA and BAS (CURB) is investigated to create a stable inter-atrial
      communication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Balloon atrial septostomy (BAS) is an important palliative therapy in patients with
      refractory pulmonary arterial hypertension. However, the incidence of spontaneous closure is
      higher, which limits the clinical utilization of this procedure. Radiofrequency catheter
      ablation (RFA) has the potential to cause irreversible damage around the rim of fenestration
      created with BAS, which might prevent the re-adhesion of the septal remnants. In addition,
      RFA on fossae ovalis might reduce the elastic recoil of local tissue and contribute to create
      larger inter-atrial fenestration with same BAS procedure. In this study, the patients between
      18 and 60 years of age who have severe pulmonary arterial hypertension associated with right
      heart failure refractory to medical therapy or severe syncopal symptoms may be eligible for
      this study (idiopathic severe pulmonary arterial hypertension or severe pulmonary arterial
      hypertension associated with repaired congenital heart disease). These patients will be
      randomized 1:1:1 to control group, single-RFA group and double-RFA group:

        1. In control group: only BAS is carried out.

        2. In single-RFA group: after BAS procedure identical to control group, RFA is performed
           immediately around the rim of created inter-atrial fenestration.

        3. In double-RFA group: the first step is RFA on fossae ovalis; and then the other two
           steps are identical to the single-RFA group (BAS and RFA around the rim of
           fenestration).

      The immediate size of created fenestration will be determined with intra-cardiac
      echocardiography, and the patency and size of fenestration will be followed up for 12 months.
      During the period of follow up, the other evaluations will include the exercise tolerance,
      cardiac index, systemic arterial oxygen saturation and so on.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The size change of the fenestration created with atrial septostomy</measure>
    <time_frame>12 months</time_frame>
    <description>The changes of the fenestration-size will be followed up in three different groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The exercise tolerance</measure>
    <time_frame>12 months</time_frame>
    <description>6-min walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The systemic arterial oxygen saturation</measure>
    <time_frame>12 months</time_frame>
    <description>The change of systemic arterial oxygen saturation after atrial septostomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization functional class</measure>
    <time_frame>12 months</time_frame>
    <description>World Health Organization functional class before and after atrial septostomy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single-RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double-RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiofrequency catheter ablation</intervention_name>
    <description>(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).</description>
    <arm_group_label>double-RFA group</arm_group_label>
    <arm_group_label>single-RFA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Balloon atrial septostomy</intervention_name>
    <description>Graded balloon atrial septostomy is performed in all patients.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>double-RFA group</arm_group_label>
    <arm_group_label>single-RFA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Idiopathic severe pulmonary arterial hypertension;

          2. Severe pulmonary arterial hypertension associated with repaired congenital heart
             disease;

          3. World Health Organization functional class III or IV with right heart failure
             refractory to medical therapy;

          4. Severe syncopal symptoms;

        Exclusion Criteria:

          1. Mean right atrial pressure &gt;20 mm Hg;

          2. Room-air resting arterial oxygen saturation &lt;85%;

          3. Left ventricular end diastolic pressure (LVEDP) &gt;18mm Hg;

          4. Pulmonary vascular resistance &gt;55 wood units/m2.

          5. Severe right ventricular failure on cardio-respiratory support

          6. The predicted one-year survival &lt;40%;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaowu Yan, PhD and MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chaowu Yan, PhD and MD</last_name>
    <phone>+8610-88322265</phone>
    <email>chaowuyan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaowu Yan, PhD and MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.</citation>
    <PMID>26320113</PMID>
  </reference>
  <reference>
    <citation>Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983 May 15;51(9):1560-1.</citation>
    <PMID>6189385</PMID>
  </reference>
  <reference>
    <citation>Sandoval J, Gaspar J, Pulido T, Bautista E, Martínez-Guerra ML, Zeballos M, Palomar A, Gómez A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998 Aug;32(2):297-304.</citation>
    <PMID>9708453</PMID>
  </reference>
  <reference>
    <citation>Kurzyna M, Dabrowski M, Bielecki D, Fijalkowska A, Pruszczyk P, Opolski G, Burakowski J, Florczyk M, Tomkowski WZ, Wawrzynska L, Szturmowicz M, Torbicki A. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007 Apr;131(4):977-83.</citation>
    <PMID>17426198</PMID>
  </reference>
  <reference>
    <citation>Allcock RJ, O'Sullivan JJ, Corris PA. Atrial septostomy for pulmonary arterial hypertension. Heart. 2003 Nov;89(11):1344-7.</citation>
    <PMID>14594898</PMID>
  </reference>
  <reference>
    <citation>Micheletti A, Hislop AA, Lammers A, Bonhoeffer P, Derrick G, Rees P, Haworth SG. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart. 2006 Jul;92(7):969-72. Epub 2005 Nov 8.</citation>
    <PMID>16278272</PMID>
  </reference>
  <reference>
    <citation>Koeken Y, Kuijpers NH, Lumens J, Arts T, Delhaas T. Atrial septostomy benefits severe pulmonary hypertension patients by increase of left ventricular preload reserve. Am J Physiol Heart Circ Physiol. 2012 Jun 15;302(12):H2654-62. doi: 10.1152/ajpheart.00072.2012. Epub 2012 Apr 20.</citation>
    <PMID>22523252</PMID>
  </reference>
  <reference>
    <citation>Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, Rodríguez A, Pulido T. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011 Dec;38(6):1343-8. doi: 10.1183/09031936.00072210. Epub 2011 Feb 24.</citation>
    <PMID>21349914</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>balloon atrial septostomy</keyword>
  <keyword>radiofrequency catheter ablation</keyword>
  <keyword>spontaneous closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

